Search - tctmd.com

Displaying 21 - 33 of 33

Sort: Relevancy | Date

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Daily News

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

L.A. McKeown

April 19, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Daily News

Poor Metabolic Health Raises Coronary Heart Disease Risk Regardless of BMI

Yael L. Maxwell

August 21, 2017

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

Presentation

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

Presenter: D. Gaudet

August 12, 2015

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

CME

Advertisement

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Poor Metabolic Health Raises Coronary Heart Disease Risk Regardless of BMI

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content